BACKGROUND: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration. METHODS: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains using the Cognitive Ability Screening Instrument among 37 patients with newly diagnosed mild stage AD taking donepezil 5 mg/d. RESULTS: Among the 9 cognitive domains in the Cognitive Ability Screening Instrument, the long-term memory domain had the highest improvement ratio (81.1%) compared with the other domains. An increased donepezil plasma concentration [mean (SD), 75.14 (32.16) ng/mL] was significantly associated with the improvement of long-term memory (P = 0.045; odds ratio, 0.959; 95% confidence interval, 0.920-0.999) after adjusting for age, sex, education, and apolipoprotein E genotype. CONCLUSIONS: Although there are some limitations in our study, these findings indicate that a higher concentration of donepezil improves long-term memory in patients with mild stage AD and imply the possible benefits in the advanced stage of AD for relatively preserved long-term memory.
BACKGROUND:Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration. METHODS: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains using the Cognitive Ability Screening Instrument among 37 patients with newly diagnosed mild stage AD taking donepezil 5 mg/d. RESULTS: Among the 9 cognitive domains in the Cognitive Ability Screening Instrument, the long-term memory domain had the highest improvement ratio (81.1%) compared with the other domains. An increased donepezil plasma concentration [mean (SD), 75.14 (32.16) ng/mL] was significantly associated with the improvement of long-term memory (P = 0.045; odds ratio, 0.959; 95% confidence interval, 0.920-0.999) after adjusting for age, sex, education, and apolipoprotein E genotype. CONCLUSIONS: Although there are some limitations in our study, these findings indicate that a higher concentration of donepezil improves long-term memory in patients with mild stage AD and imply the possible benefits in the advanced stage of AD for relatively preserved long-term memory.
Authors: A Coin; M V Pamio; C Alexopoulos; S Granziera; F Groppa; G de Rosa; A Girardi; G Sergi; E Manzato; R Padrini Journal: Eur J Clin Pharmacol Date: 2016-03-08 Impact factor: 2.953
Authors: Matthew Townsend; Andrew Whyment; Jean-Sebastien Walczak; Ross Jeggo; Marco van den Top; Dorothy G Flood; Liza Leventhal; Holger Patzke; Gerhard Koenig Journal: J Neurophysiol Date: 2016-09-21 Impact factor: 2.714
Authors: Marion Ortner; Marion Stange; Heike Schneider; Charlotte Schroeder; Katharina Buerger; Claudia Müller; Bianca Dorn; Oliver Goldhardt; Janine Diehl-Schmid; Hans Förstl; Werner Steimer; Timo Grimmer Journal: Front Pharmacol Date: 2020-05-21 Impact factor: 5.810